The FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. In fulfilling that task, OOPD evaluates scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. The office also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.Continue reading
Author Archive: AZBio
Celebrating Progress – Delivering Hope – Rare Disease Day 2013
Join AZBio in Our Virtual Celebration of Rare Disease Day 2013 – February 28, 2013Continue reading
Critical Path Institute names Martha Brumfield CEO
The Board of Directors of the Critical Path Institute (C-Path) announced today that Martha Brumfield, Ph.D., has been named interim president and chief executive officer of the organization. Brumfield, C-Path’s former director of International & Regulatory Programs, takes over immediately for Carolyn Compton, M.D., Ph.D., who will be assuming a new position at Arizona State University (ASU).Continue reading
Ground broken for new University of Arizona Cancer Center clinic in Phoenix
Ground was officially broken today on the new University of Arizona Cancer Center (UACC) at St. Joseph’s Hospital and Medical Center/Dignity Health outpatient facility in downtown Phoenix.Continue reading
Tucson ScienceWorks: Sparking a love for science in future innovators
The impact of science and technology on our lives grows with each passing day. Yet, with so much continually swirling around us, the basic workings of the world we live in have become obscured, its simple beauty hidden. It’s not that we have given up on being curious. It’s just that for many of us, the world we face seems too complex to understand.Continue reading
Small Molecules, Large Biologics and the Biosimilar Debate
From Small Molecules to Large Biologics: a look at the impact of relative size and complexity and how it impacts the biosimilar debate in the states.
Arizona’s Biosimilar Bill Goes to Committee This Week
A letter to our Arizona Legislators on Arizona’s Biosimilars BillContinue reading
Biocentury This Week Looks at Venture Capital
No one doubts the venture capital world is shrinking for life sciences.
But at least 345 venture stage biotechs around the world closed VC deals worth more than $6 billion last year. It was the second highest total in the past decade. And the total has not fallen below $5 billion in that time.Continue reading
Forbes Ranks SynCardia Among “America’s Most Promising Companies” for Second Year
SynCardia Sets New Monthly Record for Total Artificial Heart Implants in JanuaryContinue reading
UA Study: Can a Sensor Prevent Diabetic Foot Amputation?
A researchers are working with a small business partner to design an innovative technology aimed at boosting diabetic patients’ adherence to prescribed footwear.Continue reading